CMR characteristics at baseline and at the 4-month follow-up
| Baseline | 4-Month follow-up | |||||
|---|---|---|---|---|---|---|
| Overall cohort | Remodelling | Overall cohort | Remodelling | |||
| n=89 | No (n=75) | Yes (n=14) | n=89 | No (n=75) | Yes (n=14) | |
| LVEF, % | 55±10 | 56±10 | 50±7† | 59±10* | 60±9 | 52±11† |
| EDVI, mL/m2 | 73.7±13.9 | 74.7±13.8 | 68.5±14.0 | 78.6±16.3* | 76.7±14.9 | 88.9±20.2† |
| ESVI, mL/m2 | 34.2±11.5 | 34.1±11.7 | 34.6±10.5 | 32.7±12.7 | 31.1±11.8 | 41.5±14.4† |
| MMED, g | 134±30 | 134±29 | 134±38 | 131±28 | 130±26 | 135±37 |
| Infarct size, g | 25±18 | 23±17 | 36±19† | 16±15* | 15±13 | 27±19† |
| Late MVO present, n (%) | 52 (58) | 39 (52) | 13 (93)† | – | – | – |
| Transmural infarction, n (%) | 70 (79) | 56 (75) | 14 (100)† | – | – | – |
*p<0.001 vs overall cohort at baseline.
†p≤0.05 vs no remodelling.
CMR, Cardiac MR; EDVI, end-diastolic volume index; ESVI, end-systolic volume index; LVEF, left ventricular ejection fraction; MMED, myocardial mass at end diastole; MVO, microvascular obstruction.